Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chevron Corp (CVX) vs Medpace Holdings Inc (MEDP) Price & Performance

Chevron CorpTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Chevron Corp vs Medpace Holdings Inc — how do they compare? Chevron Corp trades at $196.47 (market cap $385.77B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Chevron Corp is far larger — about 22.8× Medpace Holdings Inc's market cap, and Chevron Corp pays a 3.62% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

CVXMEDP
Market Cap
$385.77B$16.90B
Volume
9,807,834
Sector
EnergyTechnology
52-Week High
$211.14$620.59
52-Week Low
$146.72$393.42
Enterprise Value
$414.31B$16.52B
Dividend Yield
3.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chevron Corp

CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).

Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Chevron Corp

Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.

Read more on CVX

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP